血清氨基酸β寡合体可能预测中年和晚年患有抑郁症的患者的治疗反应
Kentaro Shimizu1,2, Seita Yasuda2, Hitoshi Maeshima1,3
1Department of Psychiatry & Behavioral Science, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Neuropsychopharmacology reports
|March 16, 2026
概括
血清粉样β (Aβ) 寡合体可能表明抑郁症的老年人对抗抑郁药治疗的反应不佳. 这一发现表明阿尔茨海默氏症病理学与抑郁症治疗耐药性之间的潜在联系.
科学领域:
- 神经科学是一个神经科学.
- 老年精神病学是一门精神病学专业.
- 生物化学 生物化学
背景情况:
- 晚年抑郁症往往表现为对抗抑郁药物的反应减少.
- 与阿尔茨海默氏症 (AD) 和粉样β (Aβ) 负担相关的并发性抑郁症与治疗结果不佳有关.
- 血中Aβ寡合体的升高与AD病理学有关.
研究的目的:
- 调查血清Aβ寡合体与抗抑郁药治疗反应之间的关系.
- 评估Aβ小聚体是否预测中年和晚年抑郁症的治疗结果.
主要方法:
- 80名住院患有严重抑郁症 (年龄≥40岁) 的患者的观察性研究.
- 测量了Aβ40,Aβ42和Aβ寡合体的血清水平.
- 在基线和4周治疗后评估的抑郁症状.
主要成果:
- 与没有血清Aβ寡合体的患者相比,血清Aβ寡合体的患者治疗反应较少 (p=0.016).
- 血清Aβ寡合体显著影响了治疗反应,即使经过对共变量进行调整 (p=0.031).
结论:
- 血清Aβ寡合体可能成为老年人抗抑郁药治疗反应不佳的预测因素.
- 老年抑郁症治疗反应不佳可能涉及与AD相关的病理生理特征或神经脆弱性.
相关概念视频
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K